医薬原薬、化粧品有効成分は、消費者が経験する有益な効果の原因となる製品における成分です。これらの有効成分は、医薬品製造、化粧品、農薬などに広く使用されています。パーソナルケアおよび化粧品に使用される主要な有効成分には、セラミド、ナイアシンアミド、ヒアルロン酸、レチノール、ハイドロキノンおよびコウジ酸、サリチル酸、アルファヒドロキシ酸などがあります。
世界の医薬原薬、化粧品有効成分市場の主な推進要因は、化粧品およびパーソナルケア製品における使用です。肌の老化への懸念の高まりと肌の色の均一化のニーズによって、さまざまな化粧品の販売、生産が促進され、世界の医薬原薬、化粧品有効成分市場を牽引しています。過度の日焼け、環境汚染、ストレス、不健康な食生活などによって肌に悪影響を受けることから、パーソナルケアや化粧品の需要が高まっています。
医療分野で使用される有効成分とバルク有効成分は、医薬品原薬と呼ばれます。医薬品原薬は、意図した効果を生み出すあらゆる薬剤の一部です。配合薬にはさまざまな症状を治療するために複数の有効成分が使用されます。医薬品原薬市場の成長を促す主な要因としては、医薬品の研究開発活動の増加、ジェネリック医薬品の重要な役割、バイオ医薬品の消費の増加などが挙げられます。座りがちな生活習慣による世界中の慢性疾患の有病率の上昇によって医薬品の需要が増え、その結果、予測期間中は医薬品原薬市場の成長が加速するでしょう。
目次
Table of Contents
1. EXECUTIVE SUMMARY
1.1. Market Attractiveness Analysis
1.1.1. Global Active IngredientsMarket, by End Use
1.1.2. Global Active IngredientsMarket, by Region
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.3. Market Structure
3. RESEARCH METHODOLOGY
3.1. Research Process
3.2. Primary Research
3.3. Secondary Research
3.4. Market Size Estimation
3.5. Forecast Model
3.6. List of Assumptions& Assumptions
4. MARKET DYNAMICS
4.1. Introduction
4.2. Drivers
4.3. Restraints
4.4. Opportunities
4.5. Challenges
4.6. Trends
5. MARKET FACTOR ANALYSIS
5.1. Supply Chain Analysis
5.1.1. Raw Material Suppliers
5.1.2. Active IngredientsManufacturers
5.1.3. Distribution & Sales Channel
5.1.4. EndUsers
5.2. Porter’s Five Forces Model
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. Pricing Analysis(USD/Tons), by Region
5.4. Impact of COVID-19 on the Global Active IngredientsMarket
6. GLOBAL ACTIVE INGREDIENTS MARKET, BYEND USE (KILOTONS) (USD MILLION)
6.1. Introduction
6.2. Personal Care & Cosmetics
6.2.1. Market Estimates & Forecast, by Region/Country, 2019-2028
6.3. Pharmaceuticals
6.3.1. Market Estimates & Forecast, by Region/Country, 2019-2028
6.4. Agrochemicals
6.4.1. Market Estimates & Forecast, by Region/Country, 2019-2028
7. GLOBAL ACTIVE INGREDIENTS MARKET, BYREGION(KILOTONS) (USD MILLION)
7.1. Overview
7.2. North America
7.2.1. US
7.2.2. Canada
7.3. Europe
7.3.1. Germany
7.3.2. UK
7.3.3. France
7.3.4. Russia
7.3.5. Spain
7.3.6. Denmark
7.3.7. Italy
7.3.8. Rest of Europe
7.4. Asia-Pacific
7.4.1. China
7.4.2. Japan
7.4.3. India
7.4.4. South Korea
7.4.5. Australia & New Zealand
7.4.6. Indonesia
7.4.7. Rest of Asia-Pacific
7.5. Latin America
7.5.1. Brazil
7.5.2. Mexico
7.5.3. Argentina
7.5.4. Rest of Latin America
7.6. Middle East & Africa
7.6.1. Turkey
7.6.2. UAE
7.6.3. Saudi Arabia
7.6.4. South Africa
7.6.5. Rest of the Middle East & Africa
8. COMPETITIVE LANDSCAPE
8.1. Market Introduction
8.2. Recent Developments
8.2.1. Mergers/Acquisitions, Expansion, Investment, Partnership, Collaboration, Product Launch
8.3. Global Market Strategy Analysis
8.4. Competitive Benchmarking
9. COMPANY PROFILES
9.1. AkzoNobel N.V.
9.1.1. Company Overview
9.1.2. Financial Overview
9.1.3. Products Offered
9.1.4. Key Developments
9.1.5. SWOT Analysis
9.1.6. Key Strategies
9.2. Ashland
9.2.1. Company Overview
9.2.2. Financial Overview
9.2.3. Products Offered
9.2.4. Key Developments
9.2.5. SWOT Analysis
9.2.6. Key Strategies
9.3. BASF SE
9.3.1. Company Overview
9.3.2. Financial Overview
9.3.3. Products Offered
9.3.4. Key Developments
9.3.5. SWOT Analysis
9.3.6. Key Strategies
9.4. Clariant
9.4.1. Company Overview
9.4.2. Financial Overview
9.4.3. Products Offered
9.4.4. Key Developments
9.4.5. SWOT Analysis
9.4.6. Key Strategies
9.5. Evonik Industries AG
9.5.1. Company Overview
9.5.2. Financial Overview
9.5.3. Products Offered
9.5.4. Key Developments
9.5.5. SWOT Analysis
9.5.6. Key Strategies
9.6. Lonza
9.6.1. Company Overview
9.6.2. Financial Overview
9.6.3. Products Offered
9.6.4. Key Developments
9.6.5. SWOT Analysis
9.6.6. Key Strategies
9.7. Gattefossé
9.7.1. Company Overview
9.7.2. Financial Overview
9.7.3. Products Offered
9.7.4. Key Developments
9.7.5. SWOT Analysis
9.7.6. Key Strategies
9.8. Sumitomo Corporation
9.8.1. Company Overview
9.8.2. Financial Overview
9.8.3. Products Offered
9.8.4. Key Developments
9.8.5. SWOT Analysis
9.8.6. Key Strategies
9.9. DuPont
9.9.1. Company Overview
9.9.2. Financial Overview
9.9.3. Products Offered
9.9.4. Key Developments
9.9.5. SWOT Analysis
9.9.6. Key Strategies
9.10. Croda International Plc
9.10.1. Company Overview
9.10.2. Financial Overview
9.10.3. Products Offered
9.10.4. Key Developments
9.10.5. SWOT Analysis
9.10.6. Key Strategies
9.11. Eastman Chemical Company
9.11.1. Company Overview
9.11.2. Financial Overview
9.11.3. Products Offered
9.11.4. Key Developments
9.11.5. SWOT Analysis
9.11.6. Key Strategies
9.12. FMC Corporation
9.12.1. Company Overview
9.12.2. Financial Overview
9.12.3. Products Offered
9.12.4. Key Developments
9.12.5. SWOT Analysis
9.12.6. Key Strategies
9.13. Sipcam
9.13.1. Company Overview
9.13.2. Financial Overview
9.13.3. Products Offered
9.13.4. Key Developments
9.13.5. SWOT Analysis
9.13.6. Key Strategies
9.14. United Phosphorus Limited
9.14.1. Company Overview
9.14.2. Financial Overview
9.14.3. Products Offered
9.14.4. Key Developments
9.14.5. SWOT Analysis
9.14.6. Key Strategies
9.15. Nufarm Limited
9.15.1. Company Overview
9.15.2. Financial Overview
9.15.3. Products Offered
9.15.4. Key Developments
9.15.5. SWOT Analysis
9.15.6. Key Strategies
9.16. Other Companies
9.16.1. ADAMA Agricultural Solutions Limited
9.16.2. PotashCorp
9.16.3. Israel Chemicals Ltd
9.16.4. K+S AG
9.16.5. IFFCO
9.16.6. Pfizer Inc.
9.16.7. Novartis International AG
9.16.8. Merck & Co.
9.16.9. Teva Pharmaceutical Industries Ltd
9.16.10. Mylan N.V.
9.16.11. Boehringer Ingelheim
9.16.12. F. Hoffmann-La Roche AG
9.16.13. Sanofi
9.16.14. AbbVie
9.16.15. AstraZeneca
10. APPENDIX
10.1.1. Discussion Blueprint
